Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07148414Phase 2Recruiting

A Study of SPY072 in Rheumatic Disease

Role: lead

NCT07012395Phase 2Recruiting

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

Role: lead

NCT06448247Phase 1Completed

A Study of SPY001-001 in Healthy Volunteers

Role: lead

NCT06873724Phase 1Active Not Recruiting

A Study of SPY003-207 in Healthy Volunteers

Role: lead

NCT06672718Phase 1Recruiting

A Study of SPY002-091 in Healthy Volunteers

Role: lead

NCT06622070Phase 1Recruiting

A Study of SPY002-072 in Healthy Volunteers

Role: lead

All 6 trials loaded